{'fraction_non_alphanumeric': 0.02247191011235955, 'fraction_numerical': 0.0040858018386108275, 'mean_word_length': 5.621621621621622, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Anti‐Interleukin Therapy in Asthma

Asthma remains one of the most prevalent and costly diseases in the United States. Asthma accounts for a significant amount of direct medical expenditures and indirect cost from days lost at school and work. Modern understanding of its complex pathogenesis has allowed recognition of the heterogeneity of the disease across populations and the various inflammatory pathways that drive airway inflammation in asthma. Interleukins play important roles in both eosinophilic and noneosinophilic asthma, and anti‐interleukin therapy will allow for a targeted, personalized approach to asthma management. With the success of anti‐interleukin (IL) ‐4, IL‐5, and IL‐13 therapy in recent large trials among specific populations of asthmatics, it is likely that targeted anti‐interleukin therapy will be approved for use in the near future. It will be important for clinicians and pharmacists to understand their risks, benefits, and proper indications.